SLS(SLS)
SLS
ANALYST COVERAGE5 analysts
BUY
▼ -61.7%downside to target
L $2.40
Med $2.80consensus
H $3.20PRICE
Prev Close
7.08
Open
7.36
Day Range7.10 – 7.55
7.10
7.55
52W Range1.39 – 7.80
1.39
7.80
93% of range
VOLUME & SIZE
Avg Volume
7.0M
FUNDAMENTALS
P/E Ratio
-31.6x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.50
Market-like
TECHNICAL
RSI (14)
78
Overbought
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 115 days
Sep 10
Key MetricsTTM
Market Cap$1.04B
Revenue TTM$0.00
Net Income TTM-$29.46M
Free Cash Flow-$28.16M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-47.1%
Return on Assets-25.8%
Debt / Equity0.01
Current Ratio17.22
EPS TTM$-0.17
SLS News
About
σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Angelos StergiouFounder, President, Chief Executive Officer & Director
Dragan CicicSenior Vice President & Chief Development Officer
Andrew ElnatanSenior Vice President of Regulatory Affairs, CMC & Quality
John Thomas BurnsSenior Vice President & Chief Financial Officer
Stacy YeungVP, General Counsel & Corporate Secretary